Filing Details
- Accession Number:
- 0001140361-23-020315
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-25 18:43:09
- Reporting Period:
- 2023-04-21
- Accepted Time:
- 2023-04-25 18:43:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1650648 | 4D Molecular Therapeutics Inc. | FDMT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1608936 | Jacob Chacko | C/O 4D Molecular Therapeutics Inc. 5858 Horton Street #455 Emeryville CA 94608 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-04-21 | 5,000 | $9.41 | 5,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-21 | 5,000 | $20.05 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-21 | 5,000 | $0.00 | 5,000 | $9.41 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 32,500 | 2029-03-19 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022.
- The transaction was executed in multiple trades in prices ranging from $20.00 to $20.23, inclusive. The price reported in Column 4 above reflects the weighted average saleprice. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, fullinformation regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The stock option is fully vested and exercisable.
Billionaire Hedge Funds
